Jose I Herrero
Overview
Explore the profile of Jose I Herrero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mogna-Pelaez P, Riezu-Boj J, Milagro F, Clemente-Larramendi I, Esteban Echeverria S, Herrero J, et al.
Nutrients
. 2024 Dec;
16(23).
PMID: 39683591
: This study investigates the gut microbiota's role in metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on microbial and functional signatures and sex-based differences. : Using baseline data from 98...
2.
Tobaruela-Resola A, Riezu-Boj J, Milagro F, Mogna-Pelaez P, Herrero J, Elorz M, et al.
J Endocrinol Invest
. 2024 Nov;
PMID: 39549213
Purpose: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) affects one-third of the global population. Despite its high prevalence, there is a lack of minimally non-invasive diagnostic methods to assess this condition....
3.
Perdomo C, Martin-Calvo N, Ezponda A, Mendoza F, Bastarrika G, Garcia-Fernandez N, et al.
Cardiovasc Diabetol
. 2024 Aug;
23(1):308.
PMID: 39175063
Background: Albuminuria is considered an early and sensitive marker of kidney dysfunction, but also an independent cardiovascular risk factor. Considering the possible relationship among metabolic liver disease, cardiovascular disease and...
4.
Tobaruela-Resola A, Milagro F, Elorz M, Benito-Boillos A, Herrero J, Mogna-Pelaez P, et al.
J Physiol Biochem
. 2024 Aug;
PMID: 39138826
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a worldwide leading cause of liver-related associated morbidities and mortality. Currently, there is a lack of reliable non-invasive biomarkers for an accurate of...
5.
Tobaruela-Resola A, Riezu-Boj J, Milagro F, Mogna-Pelaez P, Herrero J, Elorz M, et al.
Nutrients
. 2024 Jun;
16(11).
PMID: 38892481
Metabolic dysfunction-associated steatotic liver disease (MASLD), with a prevalence of 30% of adults globally, is considered a multifactorial disease. There is a lack of effective non-invasive methods for accurate diagnosis...
6.
Mogna-Pelaez P, Riezu-Boj J, Milagro F, Herrero J, Elorz M, Benito-Boillos A, et al.
Clin Nutr
. 2024 Jun;
43(7):1770-1781.
PMID: 38861890
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern. The disease is silent, and its diagnosis is often delayed. Inflammatory markers constitute an interesting...
7.
Mogna-Pelaez P, Romo-Hualde A, Riezu-Boj J, Milagro F, Munoz-Prieto D, Herrero J, et al.
J Physiol Biochem
. 2023 Nov;
80(3):639-653.
PMID: 37996653
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease in the world. New non-invasive diagnostic tools are needed to promptly treat this disease and avoid...
8.
Perdomo C, Ezponda A, Nunez-Cordoba J, Herrero J, Bastarrika G, Fruhbeck G, et al.
Sci Rep
. 2022 Apr;
12(1):6564.
PMID: 35449229
Non-alcoholic fatty liver disease (NAFLD) is associated with cardiovascular disease morbimortality. However, it is not clear if NAFLD staging may help identify early or subclinical markers of cardiovascular disease. We...
9.
Perez-Diaz-Del-Campo N, Riezu-Boj J, Marin-Alejandre B, Monreal J, Elorz M, Herrero J, et al.
Panminerva Med
. 2022 Apr;
64(4):485-496.
PMID: 35437302
Background: Non-alcoholic fatty liver disease (NAFLD) development is linked to insulin resistance and influenced by environmental factors, but it also underlined a genetic predisposition. The aim of this research was...
10.
Serrano-Alonso M, Martin-Moreno P, Rabago G, Guillen-Grima F, Herrero J, Fernandez-Alonso M
Med Clin (Barc)
. 2021 Aug;
158(11):543-546.
PMID: 34353627
Background And Objective: We compared the efficacy and safety of standard vs. extended primary cytomegalovirus (CMV) prophylaxis in solid organ transplantation. Materials And Methods: Retrospective cohort study of CMV seronegative...